353 related articles for article (PubMed ID: 26854026)
1. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
Koschmieder S; Mughal TI; Hasselbalch HC; Barosi G; Valent P; Kiladjian JJ; Jeryczynski G; Gisslinger H; Jutzi JS; Pahl HL; Hehlmann R; Maria Vannucchi A; Cervantes F; Silver RT; Barbui T
Leukemia; 2016 May; 30(5):1018-24. PubMed ID: 26854026
[TBL] [Abstract][Full Text] [Related]
2. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms.
Chatain N; Koschmieder S; Jost E
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806517
[TBL] [Abstract][Full Text] [Related]
3. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.
Fleischman AG
Mediators Inflamm; 2015; 2015():606819. PubMed ID: 26538830
[TBL] [Abstract][Full Text] [Related]
4. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
Prick J; de Haan G; Green AR; Kent DG
Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
6. Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.
Andersen M; Sajid Z; Pedersen RK; Gudmand-Hoeyer J; Ellervik C; Skov V; Kjær L; Pallisgaard N; Kruse TA; Thomassen M; Troelsen J; Hasselbalch HC; Ottesen JT
PLoS One; 2017; 12(8):e0183620. PubMed ID: 28859112
[TBL] [Abstract][Full Text] [Related]
7. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
9. Genomics of MPN progression.
Patel AA; Odenike O
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):440-449. PubMed ID: 33275731
[TBL] [Abstract][Full Text] [Related]
10. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
Jutzi JS; Mullally A
Front Immunol; 2020; 11():2093. PubMed ID: 32983162
[TBL] [Abstract][Full Text] [Related]
11. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
Chen E; Mullally A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
13. An immune dysregulation in MPN.
Barosi G
Curr Hematol Malig Rep; 2014 Dec; 9(4):331-9. PubMed ID: 25139710
[TBL] [Abstract][Full Text] [Related]
14. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
Takenaka K
Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
[TBL] [Abstract][Full Text] [Related]
15. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
16. Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
Pandey R; Kapur R
Mol Cancer; 2015 Jun; 14():118. PubMed ID: 26062813
[TBL] [Abstract][Full Text] [Related]
17. The Microenvironment in Myeloproliferative Neoplasms.
Ramanathan G; Fleischman AG
Hematol Oncol Clin North Am; 2021 Apr; 35(2):205-216. PubMed ID: 33641864
[TBL] [Abstract][Full Text] [Related]
18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
19. [Effect of mutation on diagnosis, risk stratification, and treatment decisions in Philadelphia-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2017; 58(10):1931-1940. PubMed ID: 28978835
[TBL] [Abstract][Full Text] [Related]
20. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
